Introducing 

Prezi AI.

Your new presentation assistant.

Refine, enhance, and tailor your content, source relevant images, and edit visuals quicker than ever before.

Loading content…
Loading…
Transcript

A phase 3 trial of sebelipase alfa in lysosomal acid lipase deficiency

Cause

Conclusion

The disease is caused by an enzyme deficiency due to mutations in the acid lipase gene (LIPA), located in a specific region of chromosome 10 (10q24-q25).

In conclusion, cirrhosis and severe dyslipidemia often develop at an early age in patients with lysosomal acid lipase deficiency.

Pros and cons

Diagnosis

There are no pros

The diagnosis is confirmed by the genetic test of the LIPA gene or by an examination showing the deficiency of the lysosomal acid lipase (LAL) enzyme activity in blood leukocytes, in skin fibroblasts or in dried blood spots.

Cons:

  • Hepatomegaly
  • In severe cases, children develop cirrhosis and chronic liver failure
  • Vomiting
  • Diarrhea
  • Calcium deposits in the adrenal glandsomiting

Applications in medicine

The use of enzyme substitution therapy using the enzyme sebelipase alfa (Kanuma) lowers lipid values (such as triglycerides and cholesterol) in the blood, improves symptoms such as liver problems, and increases life expectancy. Its use has been approved in the United States and in Europe. Treatment with seblipase alfa is performed through an intravenous infusion once a week in patients with severe LAL deficiency (Wolman's disease), and once every two weeks in all other patients. With this treatment a protein called rhLAL is provided which replaces the LAL enzyme.

Sebelipase alfa

Sebelipase alfa is a recombinant human lysosomal acid lipase (rhLAL). Sebelipase alfa binds to cell surface receptors by means of glycans expressed in the protein and is subsequently internalized in lysosomes. It catalyzes the lysosomal hydrolysis of cholesterol esters and triglycerides in free cholesterol, glycerol and free fatty acids.

Applied in Ecuador

Definition

The allogeneic transplantation of hematopoietic progenitors (bone marrow or umbilical cord) has been used anecdotally, which prevents the deadly course of the disease but not the appearance of organ-specific complications such as liver cirrhosis. Recently, sebilipase, an enzymatic treatment that replaces the lysosomal acid lipase deficit, has been commercialized. One of the limiting factors for the use of substitute enzymatic therapy is its high cost, which exceeds $ 200,000 per year.

Lysosomal acid lipase deficiency

Deficiency of lysosomal acid lipase (LIPA) is a metabolic fluid storage disease that can occur in two ways:

  • Wolman's disease - The most severe form that begins early in childhood with accumulation of fat (lipids) in most tissues of the body.
  • Storage disease of cholesterol esters
Learn more about creating dynamic, engaging presentations with Prezi